Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature.
Sena AlaeikhanehshirTaiwo AjayiFrederieke H van DuijnhovenCoralie PoncetRidwan O OlaniranEsther H LipsLaura van 't VeerSuzette DelalogeIsabel T RubioAlastair M ThompsonFatima CardosoMartine J PiccartEmiel J T RutgersPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
This exploratory analysis of the MINDACT trial estimated an 8-year low LRR rate of 3.2% after BCS. The 70-gene signature was not independently predictive of LRR perhaps because of the low number of events observed and currently cannot be used in clinical decision making regarding LRR. The overall low number of events does provide an opportunity to design trials toward de-escalation of local therapy.